6505--Ustekinumab Pens/Syringes or Biosimilar
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
NAC PHARMACEUTICALS (36E797)
Contract Value
Not provided
Codes & Classification
Solicitation Number
36E79726R0006
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents3
The Department of Veterans Affairs (VA), through its National Acquisition Center (NAC) Pharmaceuticals office, has issued an active solicitation (Procurement Identifier: 36E79726R0006) seeking qualified suppliers for the provision of Ustekinumab Pens/Syringes or their biosimilar equivalents. This procurement falls under NAICS code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is classified under Product Service Code 6505, indicating a focus on pharmaceutical products.
The primary objective of this solicitation is to secure a reliable source of Ustekinumab, a biologic medication commonly used in the treatment of various autoimmune conditions, or approved biosimilar alternatives. The scope of the contract encompasses the supply and timely delivery of these pharmaceutical products in pen or syringe form, ensuring that the VA can continue to meet the therapeutic needs of its patient population. The intended outcome is to maintain uninterrupted access to high-quality, clinically effective medications for veterans under the care of the VA healthcare system.
Key requirements for this procurement include the ability to manufacture or distribute Ustekinumab or its biosimilars in compliance with all applicable federal regulations and quality standards. Offerors must demonstrate their capacity to deliver the specified products in the required forms (pens or syringes), and ensure consistent supply throughout the contract period. The solicitation may include additional technical, quality assurance, and delivery specifications, which are detailed in the attached documents available through the official notice link.
The contracting activity is managed by the NAC Pharmaceuticals office, a federal entity within the Department of Veterans Affairs. The primary point of contact for this solicitation is Christopher Carthron, who can be reached via email at [email protected] for any inquiries or clarifications regarding the opportunity.
This solicitation is currently active, with a response due date set for October 2, 2026. Interested parties are encouraged to review the full solicitation and its attachments, accessible through the official SAM.gov opportunity page (https://sam.gov/opp/1fad539d56c041da866be428416e766b/view), to ensure a comprehensive understanding of all requirements and submission instructions.
No specific set-aside requirements or special considerations have been indicated in the provided information. Contractors with proven experience in pharmaceutical manufacturing or distribution, particularly those with capabilities in biologics and biosimilars, are well-positioned to respond to this opportunity. The contract is expected to maintain consistent requirements and deliverables throughout its lifecycle, focusing on the ongoing supply of Ustekinumab or biosimilar products to support the VA’s mission of providing high-quality healthcare to veterans.